Popular Articles

Nexavar® In Combination With Chemotherapy Shown To Extend Progression-Free Survival In Patients With Advanced Breast Cancer
Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. announced that their first cooperative group-sponsored randomized Phase II trial in advanced metastatic breast cancer met its primary endpoint of progression-free survival. The study evaluated Nexavar® (sorafenib) tablets in combination with the oral chemotherapeutic, capecitabine, in patients with locally advanced or metastatic HER-2 negative breast cancer. Study findings demonstrated that the median progression-free survival was extended in patients treated with Nexavar and capecitabine compared to patients receiving capecitabine and placebo. These results were statistically significant (p-value = 0.0006). In this trial, the safety and tolerability of the combination was as expected and did not show any new or unexpected toxicities. A complete data analysis from this study is expected to be presented at an upcoming scientific meeting.

Sports & Orthopaedic Specialists Launch Program To Prevent ACL Injury And Enhance Performance
Sports & Orthopaedic Specialists, a national leader in orthopedic care for women, in collaboration with Sister Kenny Sports and Physical Therapy, launched the renowned Prevent Injury and Enhance Performance (PEP) program to the local and regional market. PEP is an exercise and training program designed to significantly reduce the incidence of ACL injury and enhance performance as an added benefit.
News of the day
FDA Confirms E. Coli O157:H7 In Prepackaged Nestlç© Toll House Refrigerated Cookie Dough
Today, the U.S. Food and Drug Administration announced that it has found E. coli O157:H7 (a bacterium that can cause serious food borne illness) in a sample of prepackaged Nestlç© Toll House refrigerated cookie dough currently under recall by the manufacturer and marketer, Nestlç© USA. The contaminated sample was collected at Nestlç©"s facility in Danville, Va. on June 25, 2009.
Public Health

ASGT 12th Annual Meeting: Incorporate Gene Therapy To Make Stem Cell Treatment Safer, More Effective

Gene therapy should be used in tandem with stem cell therapy to enhance the reliability of stem cells, provide an opportunity to limit adverse effects and increase treatment success, according to research presented at the American Society of Gene Therapy"s 12th Annual Meeting, May 30. "Stem cell therapy offers enormous potential to treat and even cure serious diseases. But wayward stem cells can turn into a runaway train without a conductor," said Ronald G. Crystal, MD, chief of the Division of Pulmonary and Critical Care Medicine at New York Presbyterian Hospital/Weill Cornell Medical Center. "This is an issue that can be dealt with and we have the technology to do that in the form of gene therapy." The challenges with stem cells are unique - once a transplant is performed, the cells go to work on their own, leaving the therapist without control of the therapy"s outcome. Gene therapy, however, provides a means for predetermining, and controlling, how the implanted stem cells will react in the patient. After implantation, stem cells multiply and differentiate into new types of cells. This ability is what gives them their unique potential as medical treatment. But problems arise when the cells differentiate incorrectly, multiply excessively, migrate to new areas of the body or form tumors. By modifying the genetic code of these cells prior to transplantation, researchers can program the cells to prevent adverse effects or self-destruct should they go awry. A couple of recent events have cast a new urgency on this research. In January, the Food and Drug Administration approved the first human trials using embryonic stem cells and, in March, the Obama administration reversed an earlier policy restricting federal funding for embryonic stem cell research. Scientists believe these steps will lead to accelerated development of stem cell therapies. Stem cells hold promise for treating a host of common diseases, including diabetes, Parkinson"s disease, cancer and others. The American Society of Gene Therapy (ASGT) 12th Annual Meeting is the world"s largest scientific meeting surrounding the latest developments in gene and cell therapy, attended by nearly 2,000 researchers from around the world and featuring 60 scientific presentations. ASGT


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):